Year: 2008
Type: editorial
Abstract: The expanding roles of magnetic resonance imaging (MRI) both at detecting (prebiopsy) and at characterizing (postbiopsy but pretreatment) prostate cancer have been demonstrated.1,2 The majority of our knowledge, however, is limited to the pretreatment characterization and only a few studies have been reported on the detection of the disease. Thus, whether prebiopsy MRI adds significant information about the presence of cancer within the prostate has not been fully understood. In this regard, the article by Kubota et al. appearing in this issue of the International Journal of Urology shed light on this topic.3 Based on a relatively small number of men with prostate specific antigen (PSA) between 4 and 10 ng/mL, whose prostates were examined by 8-core biopsy, Kubota et al. found that a T2-weighted MRI finding is an independent predictor of positive prostate biopsy, along with PSA density. The following points should be noted: Firstly, although the authors proposed an inclusion of MRI in an algorithm for prostate cancer detection, they recommend MRI study only to men with a PSA density equal to or less than 0.187 (Fig. 3 in the article). According to this algorithm, we have to perform PSA determination, transrectal ultrasound examination to determine the prostate volume and MRI if the calculated PSA density is not so high. Secondly, in their study cohort, the diagnostic accuracy of digital rectal examination (DRE) plus PSA density was higher than that of MRI plus PSA density (Table 5 in the article). Based on their results, it seems impossible for MRI to replace the DRE. Given the huge number of men with PSA in this range, their findings would not justify the remarkable cost of MRI study. Further studies are required to clarify to whom prebiopsy MRI can be recommended. Several other concerns are also raised for this study. (i) Information obtained by the T2-weighted protocol alone is limited. Other new protocols such as the diffusion-weighted protocol are required to improve the diagnostic yield of MRI itself.4 (ii) A considerable number of false negative cases would be present in their study cohort because the prostate sampling was limited to only eight cores.5–7 If extended prostate biopsy was performed, a different conclusion might be drawn from the identical study cohort. Possible contribution of MRI to the diagnosis of the disease should be clarified in a study cohort examined by extended biopsy. Although MRI has been accepted as the best imaging modality for detection, its potential for technical improvement should be further explored.
Source: International Journal of Urology
Author: Satoru Kawakami
Institution: Tokyo Medical and Dental University
Language: Spanish
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2318270807
